Menocal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Menocal

Quick Facts: Menocal (Calcitonin Salmon)

Property Description
Active ingredient Calcitonin Salmon (Salcatonin)
Form Sterile Solution for Injection; Aqueous Nasal Spray
Pharmacological class Calcium Metabolism Modifier; Peptide Hormone
General purpose Conserving bone mass; regulating high blood calcium
Origin Synthetic Polypeptide (derived from salmon species sequence)

Defining Menocal: A Synthetic Polypeptide Hormone

Menocal is a medicinal product containing the active ingredient Calcitonin Salmon (INN: Salcatonin), which is classified as a Calcium Metabolism Modifier and a Peptide Hormone. The active compound is a synthetic version of a hormone naturally occurring in the salmon species, chemically composed as a peptide of 32 amino acids. The drug is clinically recognized for its unique ability to regulate mineral balance.

The structure of Salcatonin is engineered to differ from natural human calcitonin. This modification results in a compound with a greater potency and a longer duration of action when compared to the human analogue, establishing it as the standard therapeutic agent for bone and mineral regulation. This compound is manufactured as a strictly single-ingredient formulation designed to intervene directly in the body’s homeostatic regulation of calcium.


What Type of Drug is Calcitonin Salmon and What is its General Purpose?

Calcitonin Salmon is supplied as a Sterile Aqueous Solution for administration via subcutaneous (SC) or intramuscular (IM) injection, and as an Aqueous Nasal Solution designed for intranasal use as a metered spray. These delivery methods are necessary because the active ingredient's peptide structure would be degraded and rendered ineffective if taken orally, necessitating non-oral routes to ensure its bioavailability.

The fundamental purpose of this medication is to help conserve existing bone mass and to aid in the regulation of abnormally high calcium levels in the blood. Its core mechanism involves acting as a Calcitonin Receptor Agonist, which primarily works to inhibit the function of osteoclasts—the specialized cells responsible for the dissolution and resorption of bone tissue. For instance, the medicine is commonly used in scenarios where rapid bone breakdown is occurring. By reducing the rate of bone breakdown, the drug facilitates the stabilization of the skeletal structure.

What side effects are possible with Menocal?

Possible Side Effects and Safety Information

Menocal is a product containing a combination of vitamins and minerals, including Calcium, Iron, Magnesium, Vitamin B12, and Vitamin D3. The safety profile is primarily associated with the known effects and potential interactions of these individual components.

Common Adverse Reactions

The most frequently reported adverse reactions linked to mineral supplements, such as calcium and iron, involve the gastrointestinal system. These effects may include constipation, upset stomach, nausea, or vomiting. These reactions are typically mild and often relate to the dosage or the specific salt form of the minerals being consumed.

Serious Adverse Reactions and Restrictions

High doses of certain components can lead to serious, clinically significant conditions. For instance, excessive intake of calcium and Vitamin D3 can result in hypercalcemia (high calcium levels in the blood), which can manifest as increased thirst, increased urination, confusion, or severe weakness, requiring immediate clinical attention. Individuals with pre-existing conditions such as kidney disease, sarcoidosis, or a history of kidney stones should exercise particular caution with calcium and Vitamin D intake.

Iron overload is a potential concern, and products containing iron are restricted for use in patients with conditions like hemochromatosis. Iron supplements may also cause black stools.

Safety Considerations and Interactions

Regulatory safety information often highlights the need to monitor for drug interactions. Calcium, Iron, and Magnesium may interact with certain prescription medications, including some antibiotics (like tetracyclines and fluoroquinolones) and thyroid hormone replacements (e.g., levothyroxine), by reducing their absorption and effectiveness. Furthermore, certain minerals within the product, such as calcium and iron, may compete with each other for absorption, which can affect overall nutrient availability. The product's official prescribing information provides the definitive list of precautions and restrictions, detailing the complete safety profile categorized by System-Organ Class and frequency.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Calcitonin Salmon (Menocal) typically presents as an exacerbation of known pharmacological effects. Documented clinical manifestations are generally dose-dependent and include nausea, vomiting, flushing of the face or upper body, and dizziness.

Severe adverse reactions specifically resulting from high-dose exposure have not been commonly reported. Nevertheless, immediate medical attention is required in any suspected overdose scenario. Government health authorities mandate that individuals call emergency services immediately if severe, life-threatening symptoms are observed, such as collapse, seizure activity, or trouble breathing. Emergency provision must also be ready if a serious allergic-type reaction occurs.

Management is confined to providing supportive measures for the patient’s clinical presentation. Official labeling confirms that there are no specific monitoring protocols or population-specific risks documented within the overdose section for acute cases. This approach is consistent with the regulatory statement that no specific antidote is known for Calcitonin Salmon overdose.

Overdose Management Focus Regulatory Statement
Antidote Status No specific antidote is known.
Treatment Treatment must be symptomatic and supportive.

Therapeutic Uses of Menocal

What Menocal treats: main uses and benefits

The therapeutic use of Calcitonin Salmon is generally focused on metabolic bone disorders and acute mineral imbalances. The medication is commonly used for managing conditions including Postmenopausal Osteoporosis (to mitigate bone mineral density loss), Paget's Disease of Bone, and the treatment of hypercalcemia.

It is applied across domains where short-term symptomatic assistance is needed, primarily addressing intense, sudden symptom patterns. For patients experiencing the acute, severe pain from an osteoporotic vertebral compression fracture, the medication is utilized to support symptomatic management, which contributes to easing discomfort during symptomatic periods during the immediate recovery phase. In contexts involving heightened systemic burden, such as severe hypercalcemia, the treatment is relevant for easing distressing manifestations like nausea and lethargy, supports patients during difficult episodes by easing distress.

“This medication is applied in clinical settings where short-term support is required to support symptom management and assist with comfort, especially during acute episodes.”

In chronic conditions, particularly Paget's Disease, it provides support that generally helps ease the overall symptom load related to heightened bone turnover, assisting with the management of chronic bone pain.


Quick Fact: Symptom Support Domains
The medication is commonly used to help manage acute, severe skeletal pain associated with vertebral fractures and to assist with rapidly addressing systemic distress linked to severe hypercalcemia.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Menocal (Calcitonin Salmon)

The official eligibility profile for Calcitonin Salmon is strictly defined by regulatory authorities to ensure appropriate use.

Absolute Contraindications

Menocal is contraindicated in patients with a documented hypersensitivity to Calcitonin Salmon or any components of the medicine. It is also contraindicated in patients with hypocalcemia (low calcium levels). Hypocalcemia and other mineral metabolism disorders, such as Vitamin D deficiency, must be effectively treated before treatment can begin.

Age and Physiological Restrictions

Population Regulatory Status
Pediatric Population Safety and effectiveness are not established in individuals under 18 years of age.
Pregnancy Not recommended; only permitted if judged absolutely essential by a physician.
Lactation Not recommended while breastfeeding.
Geriatric / Hepatic Impairment No evidence of reduced tolerability or need for altered dosage requirements is reported.

This profile defines use primarily for postmenopausal women (for osteoporosis), and patients with symptomatic Paget's disease or hypercalcemia, provided all mandatory exclusion criteria are met.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Menocal (Calcitonin Salmon) has a highly specific, limited profile of documented drug interactions according to government regulatory labeling. The official interaction profile is primarily defined by the pharmacokinetic and pharmacodynamic outcomes described in the prescribing information, rather than broad metabolic or dietary interactions.


Official Interaction Statements

Classification Interacting Entity Regulatory-Documented Outcome
Pharmacokinetic Modification Lithium Co-administration may lead to a reduction in plasma lithium concentrations. This is officially documented to be due to an increased urinary clearance of lithium.
Pharmacodynamic Interference Diphosphonates (prior use) Prior use of diphosphonates is documented to reduce the anti-resorptive response to Menocal, specifically in patients with Paget's disease of Bone.

Absence of Documented Interactions

The regulatory documents explicitly state that formal drug interaction studies designed to evaluate interactions with the CYP enzyme system (metabolic pathways) or with food, alcohol, or herbal products have not been performed. Consequently, no specific timing-based separation rules or restrictions regarding these substances are provided in the official labeling.

Mechanism of Action

Menocal is an inhibitor of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. This action is accomplished by direct interaction with the Receptor Activator of NF-κB Ligand (RANKL) signaling axis. Specifically, Menocal modulates the binding of RANKL to its receptor, RANK, which is expressed on the surface of osteoclast precursors and mature osteoclasts. The resultant interference with the RANKL–RANK interaction disrupts the activation of the intracellular tumor necrosis factor receptor-associated factor 6 (TRAF6) and subsequent signaling cascades. This molecular modification prevents the translocation of NF-kappaB dimers into the nucleus, which in turn reduces the transcription of pro-osteoclastogenic genes. By modifying gene expression and suppressing the required signaling for cellular differentiation, Menocal modulates the cellular ratio of osteoblast and osteoclast activity, thereby influencing the physiological process of bone resorption.

Dosage and Administration Information

How to Take Menocal

Menocal, a supplement typically containing calcium carbonate and cholecalciferol (Vitamin D3), should be used exactly as directed by a healthcare professional or as instructed on the product label. The standard dosage and administration method can vary based on the specific formulation (e.g., tablet, chewable, or nasal spray) and the individual's needs.

General Oral Tablet Use

If the preparation is an oral tablet or chewable, it is generally recommended to take it with or immediately after a meal to enhance the absorption of the calcium component, which is often calcium carbonate. Adequate Vitamin D is essential for the intestinal absorption of calcium. Follow the specific instructions for the tablet type:

  • Chewable tablets must be chewed or crushed completely before swallowing. Do not swallow chewable forms whole.
  • Swallowable tablets should be taken with a full glass of water.

Timing and Missed Doses

For consistent results, try to take your dose at the same time each day. If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and resume your regular dosing schedule. Do not take a double dose to compensate for a forgotten one.

Important Considerations

Calcium can interact with the absorption of other medications, including certain antibiotics, iron supplements, and thyroid medications. To prevent reduced absorption of these other drugs, it is generally advised to take them at least 2 to 4 hours before or after you take your calcium supplement. Always consult your healthcare provider or pharmacist regarding the proper spacing of all your medications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Menocal (Calcitonin Salmon)


Evidence for Use in Postmenopausal Osteoporosis

Menocal was studied for the condition of postmenopausal osteoporosis, which is characterized by functional limitations and bone mineral density loss. Researchers utilized long-term Randomized Controlled Trials (RCTs), some lasting up to five years, along with meta-analyses to evaluate the medicine in women typically more than five years past menopause. These studies monitored outcomes such as changes in Bone Mineral Density (BMD), primarily in the lumbar spine, and evaluated outcomes related to vertebral fracture measures. Additionally, short-term trials specifically explored outcomes related to physical discomfort, where pain scores were measured for individuals experiencing acute, disruptive episodes associated with recent vertebral compression fractures.

Research describes changes measured during the study period concerning BMD in the spine. Data show patterns related to a potential association with changes in vertebral fracture measures in certain established osteoporosis populations, but certainty remains low for the broader fracture outcomes. Regulatory bodies have noted the need for more research and have placed restrictions related to the duration of use based on their review of the evidence for this condition, meaning long-term effects are not fully established.


Evidence for Use in Paget's Disease of Bone

The medicine was evaluated in clinical trials and observational studies for the condition of Paget's disease of bone, marked by functional limitations and periods of heightened symptoms. These studies explored outcomes related to the disease by monitoring physiological strain using specific biochemical markers of bone turnover. Research also examined patient-reported outcomes describing perceived discomfort, monitoring chronic bone pain as a measured variable.

Findings describe patterns observed in the studies where measurements of elevated biochemical markers of bone turnover showed initial changes. There is limited information for long-term outcomes regarding the duration of the response after a course of treatment ends. Research has not been conducted or is insufficient to explore outcomes in individuals who have Paget's disease but are asymptomatic.


Evidence for Use in Acute Hypercalcemia

The medicine was observed in clinical settings and acute clinical trials for the condition of hypercalcemic emergencies, which are associated with acute or disruptive episodes involving temporary physiological imbalance. These studies monitored the rate and magnitude of the change in serum calcium levels over very short, defined time intervals (typically hours).

Studies consistently reported measurements of initial changes in the elevated serum calcium levels. However, research describes patterns that the observed change may be temporary, meaning the change may not be sustained over an extended period. The limited follow-up duration in acute studies means that the research provides limited insight into chronic or long-term management strategies.

Key Studies & References

  1. Calcitonin Salmon Injection USP (Cipla USA) - Indications and Usage
  2. Treatment Considerations for Hypercalcemia of Malignancy in Adults (U.S. Pharmacist)

Frequently Asked Questions (FAQ)

Common questions about Menocal (FAQ)


Q: How quickly does Menocal typically start to work?

A: The onset of action depends on the condition being treated. For managing high calcium levels in the blood (hypercalcemia), official regulatory information describes an initial effect occurring within approximately 2 hours. For the nasal spray formulation, studies indicate the active ingredient is rapidly absorbed, with the highest concentration in the blood typically occurring in under one hour.


Q: Is Menocal a maintenance drug for long-term use?

A: Regulatory documents advise caution regarding the duration of Menocal use for osteoporosis. Official warnings indicate that the potential risks of long-term use should be carefully weighed, including a reported higher incidence of certain types of cancer observed in some clinical trials. Official guidance suggests utilizing the lowest effective dose for the shortest possible duration.


Q: Are there any long-term effects associated with using Menocal?

A: Long-term use has been associated with an increased incidence of malignancies (cancers) in a meta-analysis of clinical trials. Additionally, some patients may develop circulating antibodies to the active ingredient, calcitonin salmon. This has been associated with a loss of clinical response over time.


Q: Why do some people say Menocal caused them stomach upset?

A: Stomach upset, including nausea, vomiting, and abdominal pain, is a frequently reported adverse reaction in clinical studies, particularly with the injectable form. While these are documented side effects in regulatory summaries, the precise cause for this specific reaction is not fully described in the drug's regulatory summaries.


Q: Can Menocal be crushed or split if a person has trouble swallowing pills?

A: Menocal (Calcitonin Salmon) is not supplied as a solid oral pill that can be crushed or split. The medication is manufactured as a sterile solution for injection or an aqueous nasal spray. These dosage forms are intended to be administered as directed and should not be altered or taken by mouth.


Q: What should I do if I think I missed a dose of Menocal?

A: Official patient instructions indicate that if a dose is missed, it can be administered as soon as it is remembered. However, if it is nearly the time for the next scheduled dose, the missed dose should be skipped. It is essential not to use a double dose to try and make up for a forgotten one.


Q: What happens if I take more Menocal than prescribed?

A: Taking more of the medication than prescribed may cause serum calcium levels to transiently drop below the normal range, a condition called hypocalcemia. This effect can cause physical symptoms such as muscle cramps or twitching, and individuals should be aware of these potential signs.


Q: What specific laboratory tests might be needed while on Menocal?

A: Regulatory information indicates that serum calcium levels should be monitored before and during treatment to ensure mineral balance. For some patients who are at bed rest and receiving the injectable form, periodic analysis of urine sediment may also be considered.


Q: Does Menocal affect blood pressure?

A: In postmarketing reports, which track effects observed after the drug is approved, certain cardiovascular effects, including hypertension (high blood pressure), have been noted as potential adverse reactions. The frequency of this effect is generally not known, but it is documented in official sources.


Q: How does Menocal differ from other common medicines for the same condition?

A: Menocal (Calcitonin Salmon) is chemically unique as it is classified as a peptide hormone and calcium metabolism modifier. Unlike other common treatments for bone loss, this is a large-molecule compound. It works by directly activating the calcitonin receptor to slow down the bone-resorbing cells known as osteoclasts.


Q: Why did my doctor prescribe Menocal instead of a similar drug?

A: Official indications suggest Menocal may be considered for specific patient populations. For example, it may be an option for patients with postmenopausal osteoporosis who cannot tolerate or have specific reasons preventing the use of other established therapies. Its use is limited to certain groups and durations outlined in the prescribing information.


Q: Is Menocal a type of antibiotic or pain reliever?

A: Menocal is officially classified as a Calcium Metabolism Modifier and a Peptide Hormone and is not an antibiotic. While it is studied for its use in relieving bone discomfort associated with recent vertebral fractures, its regulatory classification is not that of a general pain reliever.


Q: What is the expected timeline for seeing the effects of Menocal?

A: The timeline for seeing benefits varies by use. For Paget’s disease, improvement in specific symptoms may take several months to a year. For osteoporosis, clinical trials measuring changes in bone density were conducted over periods of up to two years.


Q: Does Menocal build up in the body over time?

A: No, the active ingredient in Menocal is known to be eliminated rapidly from the bloodstream, with a short half-life. It is primarily broken down and removed by the kidneys.


Q: Can Menocal affect birth control pills?

A: Official prescribing information states that formal drug interaction studies with oral contraceptives (birth control pills) have not been performed. As a result, no interactions regarding this class of medications are currently documented in the drug's official regulatory labeling.


Q: Can people with kidney issues take Menocal?

A: Dose adjustments are generally not considered necessary for people with mild to severe renal impairment (kidney issues). The medication is known to be primarily processed by the kidney, and its use is considered appropriate for patients with kidney problems, provided that any existing low calcium levels are corrected.


Q: Is it common to feel tired after starting Menocal?

A: Fatigue, or feeling tired, has been reported in postmarketing experience with calcitonin salmon, which tracks effects observed after the drug is approved. While this effect is noted in regulatory sources, the frequency of this adverse reaction is generally not known or is considered uncommon.


Q: Why is Menocal not approved for use in certain patient groups?

A: The drug's safety and effectiveness have not been definitively established in the pediatric population (individuals under 18 years old), resulting in restrictions for this group. Additionally, its use is generally not recommended during pregnancy or lactation due to data from animal studies suggesting potential effects on the fetus and an inhibitory effect on milk production.


Q: Does Menocal interact with common remedies like ginger or turmeric?

A: Official documents explicitly state that formal drug interaction studies with herbal products or dietary supplements, including common remedies like ginger or turmeric, have not been conducted. Therefore, the official prescribing information does not provide any specific restrictions regarding these substances.


Q: Do the side effects of Menocal usually go away after a few days?

A: Reported side effects may occur that typically do not require medical intervention. Regulatory information suggests that these effects may diminish during treatment as the body adjusts to the medication.


Q: Are there different strengths or dosages of Menocal?

A: Yes, there are different forms and standardized strengths. The nasal spray formulation is available in one specific strength per spray (200 USP Units). The injectable solution is also available in one concentration but allows for the specific dosage to be varied by the healthcare provider based on the condition being managed.


Q: Is there a generic version of Menocal available?

A: Yes, the active ingredient, Calcitonin Salmon, is available as a generic medicine from various manufacturers.


Q: Is hair loss a reported side effect of Menocal?

A: Hair loss, or alopecia, has been noted in postmarketing experience with calcitonin salmon. This is tracked in regulatory records but is not generally considered one of the common or frequently reported adverse reactions.


Q: Can Menocal cause insomnia or change my sleep patterns?

A: Insomnia (trouble sleeping) has been reported as an adverse reaction in postmarketing experience with the medication. While it is a documented effect in official sources, the frequency of this change in sleep patterns is generally not widely known.


Q: Can Menocal be taken with pain relievers like ibuprofen or acetaminophen?

A: Formal drug interaction studies with acetaminophen have not been performed. However, some regulatory-cited documents have indicated that drugs like ibuprofen may decrease the rate at which calcitonin salmon is eliminated from the body, which could potentially result in higher levels of Menocal in the system.


Q: Does the time of day matter when taking Menocal?

A: For the nasal spray formulation, official instructions recommend trying to use the spray around the same time every day. This practice may help in maintaining a consistent dosing schedule.

How should Menocal be stored and disposed of?

How to Store and Dispose of Menocal

Storage and disposal requirements for Menocal (Calcitonin Salmon) are strictly defined by regulatory documents to preserve the integrity of the peptide and ensure safe handling.

Storage Conditions

Unopened product must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F) in its original carton for protection from light. The product must not be frozen and must be discarded if freezing occurs.

Stability and Child Safety

An opened multi-dose injection vial must be discarded after 28 days, even if refrigerated. An opened nasal spray is stable at room temperature (below 25 C) but must be discarded after 30 days.

The medication must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired product must not be disposed of via wastewater or household waste. Discarding must be done through local regulatory requirements or an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Menocal found in:

A-Z Index: